These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37037733)

  • 1. Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China.
    Gong Y; Yao X; Peng J; Ma Y; Fang Y; Yan K; Jiang M
    Am J Prev Med; 2023 Jul; 65(1):155-164. PubMed ID: 37037733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
    Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
    Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
    Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.
    Minozzi S; Lytras T; Gianola S; Gonzalez-Lorenzo M; Castellini G; Galli C; Cereda D; Bonovas S; Pariani E; Moja L
    EClinicalMedicine; 2022 Apr; 46():101331. PubMed ID: 35360146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
    Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
    [No Abstract]   [Full Text] [Related]  

  • 6. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
    Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
    Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model.
    Van Bellinghen LA; Meier G; Van Vlaenderen I
    PLoS One; 2014; 9(6):e98437. PubMed ID: 24905235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
    Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
    BMC Med; 2017 Sep; 15(1):166. PubMed ID: 28882149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
    Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
    Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for preventing influenza in people with asthma.
    Cates CJ; Rowe BH
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD000364. PubMed ID: 23450529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands.
    de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ
    Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.
    Helmeke C; Gräfe L; Irmscher HM; Gottschalk C; Karagiannis I; Oppermann H
    PLoS One; 2015; 10(4):e0122910. PubMed ID: 25885063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents.
    Tarride JE; Burke N; Von Keyserlingk C; O'Reilly D; Xie F; Goeree R
    Clinicoecon Outcomes Res; 2012; 4():287-98. PubMed ID: 23055756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States.
    Poehling KA; Caspard H; Peters TR; Belongia EA; Congeni B; Gaglani M; Griffin MR; Irving SA; Kavathekar PK; McLean HQ; Naleway AL; Ryan K; Talbot HK; Ambrose CS
    Clin Infect Dis; 2018 Feb; 66(5):665-672. PubMed ID: 29029064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
    Meier G; Gregg M; Poulsen Nautrup B
    J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.